AbemaImmune (Breast Cancer) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn about the effects of endocrine therapy and CDK4/6 inhibitors (abemaciclib) on the immune system of people with advanced ER+ breast cancer.

What is the Condition Being Studied?

Metastatic ER+ Breast Cancer

Who Can Participate in the Study?

Adults who:
- Are diagnosed with metastatic ER+ breast cancer
- Have not received treatment yet

For more information about who can join this study, please contact the study team at 919-660-1278.

Age Group

What is Involved?

If you choose to join this study you will:
- Have physical exams
- Have blood draws
- Have heart scans (EKG)
- Have imaging scans
- Have tissue samples taken (biopsies)
- Take abemaciclib combined with an endocrine therapy as directed by your doctor

Study Details

Full Title
Evaluation of the effects of endocrine therapy and abemaciclib on host and tumor immune cell repertoire/function in advanced ER+/HER2- breast cancer
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00103625
NCT: NCT04352777
Phase IV
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center